News

E2F4-based gene therapy improves pathology in a mice model of Alzheimer’s disease

The Spanish biotechnology company Tetraneuron, in collaboration with Dr. José María Frade’s research group at the Cajal Institute (CSIC), has published promising results in the prestigious scientific journal Neurotherapeutics. E2F4-based gene therapy is able to mitigate the main molecular, cognitive and behavioral alterations associated with Alzheimer’s disease through a multifactorial…